Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515).

HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515). J Clin Oncol. 2011 May 20; 29(15_suppl):TPS113.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.